|Day Low/High||34.83 / 35.35|
|52 Wk Low/High||30.89 / 59.00|
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AXE, CECE, EMN, FC, NNI, PDCO, SAH, SAMG, WERN Downgrades: ATW, CERN, IPXL, NVO, OMCL, PHII, PHIIK, PLKI, SVT Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
The American Diabetes Association, JDRF, The New York Stem Cell Foundation Research Institute and Novo Nordisk Inc. Unite in the Battle Against Diabetes
MannKind bulls -- the rainbow-hued unicorns of the investment world -- believe the company's marketing efforts will succeed. They're wrong.
Stock futures are tumbling Wednesday but are well off their lows as Republican Donald Trump is elected the next president of the United States in a surprising victory.
The threat of a government clampdown on drug prices is off the table with Clinton's defeat, while wider support for defensive stocks helped push pharmaceuticals higher.
Cramer shares his views on price war victims. Nike, Allergan and Netflix are among the stocks discussed.
Pfizer, Bayer, Shire are among rivals bracing for Roche's ACE910.
Shares are trading at less than 12.5x 2017's EPS estimates and should rise soon.
Today there was a virtual vacuum of good news in the stock market.
We have to ask: where is the cash flow to pay off the debt, if any important prices are rolled back?
Look out below when it comes to margins, as the price wars extend to sneakers, drugs and others.
In a "take no pain, take no prisoners" market, health care stocks languish.
Economic data in France disappoints; Germany and U.K. beat expectations.
The Danish drugs maker halves targets for operating profit growth.
Pharma group Sanofi rises on improved guidance and RBS gains after a third-quarter profit beat.
Forward-looking purchasing managers' indices and earnings from beleaguered lender Deutsche Bank feature among the other release highlights.
Shares in the stock decline only marginally as the pharmaceuticals group sticks with its full-year forecast.
Profiting from these companies' steady long-term gains requires patience.
Novo Nordisk (NVO) is developing new types of insulin, such as a pill-based form, in response to growing competitive pressures.
Novo is 'not yet screamingly cheap, but it is certainly approaching great value.'
Shares of Novo Nordisk were lower Thursday after announcing layoffs across its global business.
The Danish pharmaceuticals maker is facing tighter margins and tougher competition in the U.S.
Energy stocks rise even as oil prices give up initial gains.
UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.
The ability to exit pricey shares with the chance to buy them back cheaper occurs with regularity.
Novo Nordisk (NVO) stock rating was increased to 'buy' at Deutsche Bank.